title: L-dopa treatment duration versus Parkinson's disease progression: the dorsal-ventral divide.
authors: Pauline
authors: P
authors: Belujon
authors: Anthony A
authors: AA
authors: Grace
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects*; D001479:Basal Ganglia / Q000503:physiopathology*; D015259:Dopamine Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents
references: J Neurosci. 1995 Sep;15(9):6157-66
references: 7666198
references: Neuropsychologia. 2000;38(5):596-612
references: 10689037
references: Cereb Cortex. 2001 Dec;11(12):1136-43
references: 11709484
references: Mov Disord. 2008;23 Suppl 3:S560-9
references: 18781673
references: Brain Res Brain Res Rev. 2000 Mar;31(2-3):330-41
references: 10719160
references: Mov Disord. 2010 Aug 15;25(11):1568-76
references: 20623773
references: Neurosci Biobehav Rev. 2006;30(1):1-23
references: 15935475
references: Curr Opin Neurol. 2005 Aug;18(4):411-7
references: 16003117
references: J Neurophysiol. 1986 Nov;56(5):1439-61
references: 3794777
references: Brain Res. 1990 Aug 13;525(1):36-44
references: 2123121
references: Nat Neurosci. 2005 Nov;8(11):1481-9
references: 16251991
references: Mov Disord. 2013 Feb;28(2):153-60
references: 23165957